company background image
NGNE logo

Neurogene NasdaqGM:NGNE Stock Report

Last Price

US$40.27

Market Cap

US$555.6m

7D

6.2%

1Y

n/a

Updated

17 Sep, 2024

Data

Company Financials +

Neurogene Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Neurogene
Historical stock prices
Current Share PriceUS$40.27
52 Week HighUS$53.00
52 Week LowUS$12.49
Beta0
11 Month Change14.99%
3 Month Change32.82%
1 Year Changen/a
33 Year Changen/a
5 Year Changen/a
Change since IPO166.69%

Recent News & Updates

Recent updates

Neurogene Stock: Gene Therapy Specialist May Break Chain Of Failed Mergers

Mar 26

Shareholder Returns

NGNEUS BiotechsUS Market
7D6.2%2.4%3.0%
1Yn/a20.4%25.3%

Return vs Industry: Insufficient data to determine how NGNE performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how NGNE performed against the US Market.

Price Volatility

Is NGNE's price volatile compared to industry and market?
NGNE volatility
NGNE Average Weekly Movement12.4%
Biotechs Industry Average Movement10.2%
Market Average Movement6.4%
10% most volatile stocks in US Market15.2%
10% least volatile stocks in US Market3.1%

Stable Share Price: NGNE has not had significant price volatility in the past 3 months.

Volatility Over Time: NGNE's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a91Rachel McMinnwww.neurogene.com

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC.

Neurogene Inc. Fundamentals Summary

How do Neurogene's earnings and revenue compare to its market cap?
NGNE fundamental statistics
Market capUS$555.61m
Earnings (TTM)US$2.36m
Revenue (TTM)US$925.00k

221.3x

P/E Ratio

565.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NGNE income statement (TTM)
RevenueUS$925.00k
Cost of RevenueUS$52.98m
Gross Profit-US$52.05m
Other Expenses-US$54.41m
EarningsUS$2.36m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.18
Gross Margin-5,627.03%
Net Profit Margin255.57%
Debt/Equity Ratio0%

How did NGNE perform over the long term?

See historical performance and comparison